StockData
Zura Bio Ltd logo

Zura Bio Ltd (ZURA) stock

ZURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 5/30
$0.97−0.07 (-6.75%)

Close on Nov 18, 2026Market cap $92.96MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$92.96M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
-69.86%

Fundamentals

Net income
-$93.53M
EPS, diluted
-$1.11
Free cash flow
-$64.94M
Diluted shares
128M

Trading

Next earnings
Mar 18, 2027 (estimated, during market hours)
Previous close
$1.03
Open
$1.01
Day's range
$0.94 – $1.05
Volume
3,028,490
Average volume (20 days)
7,771,853
52-week range
$0.93 – $7.44
RSI (14 days)
24.5
Volatility (1 year)
109.1%
Relative volume
0.92×

On 2 of our idea lists: Net-nets, More cash than they're worth

Market cap history

Month-end market cap since 2023, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodZURAS&P 500DifferenceZURA per yearS&P 500 per year
1 month-75.1%-4.3%−70.8 pts
3 months-83.3%-4.6%−78.7 pts
Year to date-81.6%+7.9%−89.5 pts
1 year-74.8%+11.8%−86.6 pts
3 years-77.2%+68.0%−145.1 pts-38.9%+18.9%
5 years-90.3%+66.2%−156.5 pts-37.2%+10.7%

Five years at a glance

Fiscal years 2021 to 2025 and trailing twelve months, USD

Operating income

-$102.00M

Net income

-$93.53M

EPS, diluted

-$1.11

Free cash flow

-$64.94M
Reported periodTrailing twelve months

Press releases

Releases Zura Bio filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Zura Bio

Biological Products, (No Diagnostic Substances)

Zura Bio is a clinical-stage biotechnology company focused on developing therapies for individuals suffering from autoimmune and inflammatory disorders. The company’s pipeline comprises three licensed drug candidates: tibulizumab, a bispecific antibody designed to inhibit both IL-17A and BAFF; crebankitug, a monoclonal antibody targeting IL-7 receptor alpha; and torudokimab, a monoclonal antibody directed against IL-33. Rather than serving commercial customers, the firm evaluates its experimental treatments in adult clinical trial participants, with tibulizumab undergoing evaluation for hidradenitis suppurativa and diffuse cutaneous systemic sclerosis.

Company profile, executives and history

Zura Bio stock: common questions

What is Zura Bio's stock price?

ZURA closed at $0.97 on Nov 18, 2026, down 6.75% on the day. Over the past 52 weeks it traded between $0.93 and $7.44.

What is Zura Bio's market cap?

Zura Bio was worth $92.96M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is ZURA's P/E ratio?

Zura Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.11), so it has no meaningful P/E ratio.

Does Zura Bio pay a dividend?

No. Zura Bio has not paid a cash dividend over the last twelve months.

When does Zura Bio report earnings next?

Zura Bio is expected to report Q4 FY2026 results on Mar 18, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.

How has ZURA stock performed over the past year?

Including dividends, ZURA returned -74.8% over the past year, against +11.8% for the S&P 500.

How many ZURA shares are sold short?

8M shares were sold short at the latest FINRA report, 14.66% of the float, or 1.8 days of average trading volume.

Who are Zura Bio's competitors?

Companies most similar to Zura Bio by business, industry and size include KYMR, CGEM, IMA, IMVT, JSPR.

See a number that looks wrong?